1406P Interim results of a phase II trial of sacituzumab govitecan (SG) in patients (Pts) with metastatic castration resistant prostate cancer (mCRPC) progressing on androgen receptor signaling inhibitors (ARSI)Jessica D. Lang, Christos E. Kyriakopoulos, Susan F. Slovin et al.|Annals of Oncology|2022Cited by 8